Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.6 USD | +9.50% | +12.53% | +16.10% |
May. 09 | Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.10% | 620M | C- | ||
+51.85% | 57.87B | B- | ||
+41.42% | 40.25B | A | ||
-5.25% | 39.94B | B | ||
-5.16% | 28.54B | C | ||
+12.79% | 26.4B | B- | ||
-20.18% | 19.33B | B | ||
+30.88% | 12.4B | C+ | ||
+0.61% | 12.23B | B+ | ||
+25.06% | 12.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHAT Stock
- Ratings Phathom Pharmaceuticals, Inc.